Literature DB >> 27329806

Understanding the mechanisms of faecal microbiota transplantation.

Alexander Khoruts1, Michael J Sadowsky2.   

Abstract

This Review summarizes mechanistic investigations in faecal microbiota transplantation (FMT), which has increasingly been adapted into clinical practice as treatment for Clostridium difficile infection (CDI) that cannot be eliminated with antibiotics alone. Administration of healthy donor faecal microbiota in this clinical situation results in its engraftment and restoration of normal gut microbial community structure and functionality. In this Review, we consider several main mechanisms for FMT effectiveness in treatment of CDI, including direct competition of C. difficile with commensal microbiota delivered by FMT, restoration of secondary bile acid metabolism in the colon and repair of the gut barrier by stimulation of the mucosal immune system. Some of these mechanistic insights suggest possibilities for developing novel, next-generation CDI therapeutics. FMT might also have potential applications for non-CDI indications. The gut can become a reservoir of other potential antibiotic-resistant pathogens under pressure of antibiotic treatments, and restoration of normal microbial community structure by FMT might be a promising approach to protect against infections with these pathogens as well. Finally, FMT could be considered for multiple chronic diseases that are associated with some form of dysbiosis. However, considerable research is needed to optimize the FMT protocols for such applications before their therapeutic promise can be evaluated.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27329806      PMCID: PMC5909819          DOI: 10.1038/nrgastro.2016.98

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  106 in total

1.  Ursodeoxycholic Acid Inhibits Clostridium difficile Spore Germination and Vegetative Growth, and Prevents the Recurrence of Ileal Pouchitis Associated With the Infection.

Authors:  Alexa R Weingarden; Chi Chen; Ningning Zhang; Carolyn T Graiziger; Peter I Dosa; Clifford J Steer; Megan K Shaughnessy; James R Johnson; Michael J Sadowsky; Alexander Khoruts
Journal:  J Clin Gastroenterol       Date:  2016-09       Impact factor: 3.062

2.  Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life.

Authors:  Fredrik Bäckhed; Josefine Roswall; Yangqing Peng; Qiang Feng; Huijue Jia; Petia Kovatcheva-Datchary; Yin Li; Yan Xia; Hailiang Xie; Huanzi Zhong; Muhammad Tanweer Khan; Jianfeng Zhang; Junhua Li; Liang Xiao; Jumana Al-Aama; Dongya Zhang; Ying Shiuan Lee; Dorota Kotowska; Camilla Colding; Valentina Tremaroli; Ye Yin; Stefan Bergman; Xun Xu; Lise Madsen; Karsten Kristiansen; Jovanna Dahlgren; Jun Wang
Journal:  Cell Host Microbe       Date:  2015-06-10       Impact factor: 21.023

3.  Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain.

Authors:  François Lamontagne; Annie-Claude Labbé; Olivier Haeck; Olivier Lesur; Mathieu Lalancette; Carlos Patino; Martine Leblanc; Michel Laverdière; Jacques Pépin
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

Review 4.  Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life.

Authors:  Sushrut Jangi; J Thomas Lamont
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-07       Impact factor: 2.839

5.  Colonic absorption of unconjugated bile acids: perfusion studies in man.

Authors:  H S Mekhjian; S F Phillips; A F Hofmann
Journal:  Dig Dis Sci       Date:  1979-07       Impact factor: 3.199

6.  Regulation of bile acid synthesis in humans: effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7 alpha-hydroxylation rates in vivo.

Authors:  M Bertolotti; N Abate; P Loria; M Dilengite; F Carubbi; A Pinetti; A Digrisolo; N Carulli
Journal:  Hepatology       Date:  1991-11       Impact factor: 17.425

Review 7.  Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics.

Authors:  A F Hofmann; L R Hagey
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

8.  Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile.

Authors:  Charlie G Buffie; Vanni Bucci; Richard R Stein; Peter T McKenney; Lilan Ling; Asia Gobourne; Daniel No; Hui Liu; Melissa Kinnebrew; Agnes Viale; Eric Littmann; Marcel R M van den Brink; Robert R Jenq; Ying Taur; Chris Sander; Justin R Cross; Nora C Toussaint; Joao B Xavier; Eric G Pamer
Journal:  Nature       Date:  2014-10-22       Impact factor: 49.962

9.  Long-term changes of bacterial and viral compositions in the intestine of a recovered Clostridium difficile patient after fecal microbiota transplantation.

Authors:  Felix Broecker; Jochen Klumpp; Markus Schuppler; Giancarlo Russo; Luc Biedermann; Michael Hombach; Gerhard Rogler; Karin Moelling
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-01

10.  Culturing of 'unculturable' human microbiota reveals novel taxa and extensive sporulation.

Authors:  Hilary P Browne; Samuel C Forster; Blessing O Anonye; Nitin Kumar; B Anne Neville; Mark D Stares; David Goulding; Trevor D Lawley
Journal:  Nature       Date:  2016-05-04       Impact factor: 49.962

View more
  140 in total

1.  Synthesis and Biological Evaluation of Bile Acid Analogues Inhibitory to Clostridium difficile Spore Germination.

Authors:  Kristen L Stoltz; Raymond Erickson; Christopher Staley; Alexa R Weingarden; Erin Romens; Clifford J Steer; Alexander Khoruts; Michael J Sadowsky; Peter I Dosa
Journal:  J Med Chem       Date:  2017-04-12       Impact factor: 7.446

Review 2.  Nutritional modulation of the intestinal microbiota; future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease.

Authors:  Vincent C Lombardi; Kenny L De Meirleir; Krishnamurthy Subramanian; Sam M Nourani; Ruben K Dagda; Shannon L Delaney; András Palotás
Journal:  J Nutr Biochem       Date:  2018-04-19       Impact factor: 6.048

3.  The only thing that stops a bad microbiome, is a good microbiome.

Authors:  Jessica R Galloway-Peña; Robert R Jenq
Journal:  Haematologica       Date:  2019-08       Impact factor: 9.941

Review 4.  Challenges and emerging systems biology approaches to discover how the human gut microbiome impact host physiology.

Authors:  Gordon Qian; Joshua W K Ho
Journal:  Biophys Rev       Date:  2020-07-07

Review 5.  The Present Status of Fecal Microbiota Transplantation and Its Value in the Elderly.

Authors:  Yao-Wen Cheng; Monika Fischer
Journal:  Curr Treat Options Gastroenterol       Date:  2017-09

6.  Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease.

Authors:  Krista M Newman; Kevin M Rank; Byron P Vaughn; Alexander Khoruts
Journal:  Gut Microbes       Date:  2017-01-19

7.  Clostridium difficile Infection and the Role of Adaptive Immunity in the Microbiome.

Authors:  Monika Fischer
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-05

8.  Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: A promising treatment approach.

Authors:  Monika Fischer; Brian Sipe; Yao-Wen Cheng; Emmalee Phelps; Nicholas Rogers; Sashidhar Sagi; Matthew Bohm; Huiping Xu; Zain Kassam
Journal:  Gut Microbes       Date:  2016-12-21

9.  Capsulized faecal microbiota transplantation ameliorates post-weaning diarrhoea by modulating the gut microbiota in piglets.

Authors:  Wenjie Tang; Daiwen Chen; Bing Yu; Jun He; Zhiqing Huang; Ping Zheng; Xiangbing Mao; Yuheng Luo; Junqiu Luo; Quyuan Wang; Huifen Wang; Jie Yu
Journal:  Vet Res       Date:  2020-04-16       Impact factor: 3.683

10.  An indisputable role of NHE8 in mucosal protection.

Authors:  Claudio Bernardazzi; Hua Xu; Huan Tong; Daniel Laubitz; Vanessa Figliuolo da Paz; Leslie Curiel; Fayez K Ghishan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-08-05       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.